利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.09 秒)

    USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL
    36.
    发明申请
    USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL 审中-公开
    用于抑制血浆胰岛素水平的二氧化氮的使用

    公开(公告)号：WO2009045101A1

    公开(公告)日：2009-04-09

    申请号：PCT/NL2008/050629

    申请日：2008-10-02

    申请人： Coöperatieve MIRzorg U.A., Arnhem ,  DE BOER, Johannes Mathijs Maria

    发明人： DE BOER, Johannes Mathijs Maria

    IPC分类号： A61K31/00 ,  A61K31/549 ,  A61P3/08

    CPC分类号： A61K31/00 ,  A61K31/549

    摘要： The present invention relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin leveland/or postabsorptive insulin level in a mammal in need thereof, wherein the fasting and/or postabsorptive plasma insulin level is reduced to about 5 mU/1 or less. The present invention also relates to the use ofa potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof,said method comprising orally administering to said mammal in need thereofa daily dosage of about 5 mg to about 1200 mg, calculated on a Diazoxide active weight basis.

    摘要翻译： 本发明涉及钾通道活化剂在制备用于抑制有需要的哺乳动物中的空腹血浆胰岛素水平和/或吸收后胰岛素水平的药物中的用途，其中禁食和/或吸收后血浆胰岛素水平降低至 约5mU / l以下。 本发明还涉及钾通道活化剂在制备用于抑制有需要的哺乳动物中空腹血浆胰岛素水平和/或吸收后胰岛素水平的药物中的用途，用于治疗或预防肥胖，肥胖相关疾病和病症等 涉及有需要的哺乳动物体重增加的疾病和病症，所述方法包括口服给予需要的所述哺乳动物基于二氮嗪活性重量计算的约5mg至约1200mg的日剂量。

    THERAPY FOR COMPLICATIONS OF DIABETES
    37.
    发明申请
    THERAPY FOR COMPLICATIONS OF DIABETES 审中-公开
    治疗糖尿病的药物

    公开(公告)号：WO2009026517A2

    公开(公告)日：2009-02-26

    申请号：PCT/US2008074013

    申请日：2008-08-22

    申请人： GILEAD COLORADO INC ,  RODEN ROBERT L ,  GORCZYNSKI RICHARD J ,  GERBER MICHAEL J

    发明人： RODEN ROBERT L ,  GORCZYNSKI RICHARD J ,  GERBER MICHAEL J

    IPC分类号： A61K31/505 ,  A61P13/12

    CPC分类号： A61K31/505 ,  A61K9/0053 ,  A61K31/4025 ,  A61K31/549 ,  A61K45/06

    摘要： A selective ETA receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome is disclosed. A selective ETA receptor antagonist for use in treating a complex of comorbidities in an elderly diabetic human subject, wherein the selective ETA receptor antagonist is for administration in combination or as adjunctive therapy with (a) at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension, and optionally (b) at least one antihypertensive other than a selective ETA receptor antagonist is disclosed. Further, a therapeutic combination comprising a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist is disclosed.

    摘要翻译： 公开了用于增加糖尿病性肾病和/或代谢综合征的人类受试者血糖控制和/或胰岛素敏感性的方法中的选择性ETA受体拮抗剂。 一种选择性ETA受体拮抗剂，其用于治疗老年糖尿病人受试者的合并症复合物，其中所述选择性ETA受体拮抗剂用于联合给药或作为辅助治疗，与（a）至少一种另外的药剂是（i）其它 公开了选择性ETA受体拮抗剂和（ii）有效治疗糖尿病和/或除了高血压之外的所述合并症中的至少一种，以及任选地（b）除了选择性ETA受体拮抗剂之外的至少一种抗高血压药。 此外，公开了包含选择性ETA受体拮抗剂和除选择性ETA受体拮抗剂之外的至少一种抗糖尿病，抗肥胖症或抗脂肪代谢剂的治疗组合。

    IMPROVED ORGAN PROTECTION, PRESERVATION AND RECOVERY
    38.
    发明申请
    IMPROVED ORGAN PROTECTION, PRESERVATION AND RECOVERY 审中-公开
    改进机构保护，保护和恢复

    公开(公告)号：WO2009012534A1

    公开(公告)日：2009-01-29

    申请号：PCT/AU2008/001086

    申请日：2008-07-25

    申请人： HIBERNATION THERAPEUTICS LIMITED ,  DOBSON, Geoffrey

    发明人： DOBSON, Geoffrey

    IPC分类号： A01N1/02 ,  A61K31/549 ,  A61K31/167 ,  A61P41/00 ,  A61K31/4406

    CPC分类号： A61K31/7076 ,  A01N1/02 ,  A01N1/0226 ,  A61K31/167 ,  A61K31/4406 ,  A61K31/549 ,  A61K45/06 ,  A61K2300/00

    摘要： This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods for reducing damage to a cell, tissue or organ comprise administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent. The methods may further include postconditioning the cell, tissue or organ.

    摘要翻译： 本申请描述了组合物，治疗方法和制备用于在缺血，再灌注或缺血或创伤后减少对细胞，组织或器官的损伤或损伤的药物的方法。 减少对细胞，组织或器官的损伤的方法包括施用有效量的组合物，包括（i）钾通道开放剂或激动剂和/或腺苷受体激动剂; 和（ii）抗心律失常药。 所述方法还可以包括对细胞，组织或器官进行后处理。